Want to join the conversation?
$ABBV said that the company expects mid teens revenue growth on operational basis for 2016, excluding roughly 2% negative impact from exchange. The company expects HUMIRA sales growth to be in the high teens in the US and mid single digit internationally during the year.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.